Bajaj Healthcare launches COVID drug favipiravir under brand name Favijaj in India
Advertisement
New Delhi: Drug firm Bajaj Healthcare on Tuesday announced the launch of its antiviral Favipiravir tablets under the brand name ''Favijaj'' used for the treatment of mild to moderate COVID-19 infections in the country.
The company has received approval from India''s drug regulator DCGI to manufacture and market the tablets, Bajaj Healthcare said in a BSE filing.
"We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure and offer patients much-needed and timely therapy options," Bajaj Healthcare Joint MD Anil Jain said.
The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team, Bajaj Healthcare said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.